M. Stuschke et Hd. Thames, Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials, RADIOTH ONC, 51(2), 1999, pp. 113-121
Citations number
41
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Purpose: A therapeutic benefit can be achieved by hyperfractionation (HF) i
f tumours have small fractionation sensitivities characterized by alpha/bet
a values greater than those for late effects of dose limiting normal tissue
s. It is the purpose of the present paper to estimate alpha/beta values for
head and neck carcinomas from randomized HF trials.
Materials and methods: Maximum likelihood estimates of the alpha/beta ratio
were obtained from tumour control data from the randomized HF trials using
the LQ model and a legit or probit type dose-response curve. A joint analy
sis of five randomized HF trials for head and neck carcinomas was performed
to estimate overall alpha/beta and gamma 50 values for tumour control. In
addition, alpha/beta ratios for the individual trials were estimated using
fixed gamma 50 values (characteristic quantifying the steepness of dose-res
ponse curves) between 1.4 and 5 for rumours.
Results: An overall gamma 50 of 3.1 (1.5-4.7) was estimated for the dose-tu
mour control relation from the HF trials, assuming a legit or probit dose-r
esponse curve. The tumours showed small fractionation sensitivities charact
erized by an overall alpha/beta of 10.5 (6.5-29) Gy. One trial allowed quan
titative estimation of the alpha/beta values for late normal tissue damage:
The alpha/beta estimate for late effects of grade 2 + was 4.0 (3.3-5.0) Gy
, assuming a fixed gamma 50 of 5 and was even smaller for smaller gamma 50
values.
Conclusion: Head and neck carcinomas showed small fractionation sensitiviti
es with alpha/beta values greater than those typical for bone, soft tissues
, and skin, as well as steep dose response curves. Thus, important prerequi
sites for improving the therapeutic benefit of radiotherapy of head and nec
k carcinomas by HF are fulfilled for patients who met the accession criteri
a of the trials. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved
.